Article
Hematology
Neda Alrawashdh, Joann Sweasy, Brian Erstad, Ali McBride, Daniel O. Persky, Ivo Abraham
Summary: The relative survival rates for CLL patients diagnosed between 1985 and 2015 improved significantly, especially after the introduction of targeted therapies. The proportions of long-term survivors varied by age and gender.
ANNALS OF HEMATOLOGY
(2021)
Article
Medicine, General & Internal
Barbara Eichhorst, Carsten U. Niemann, Arnon P. Kater, Moritz Fuerstenau, Julia von Tresckow, Can Zhang, Sandra Robrecht, Michael Gregor, Gunnar Juliusson, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Vesa Lindstrom, Caspar da Cunha-Bang, Christof Schneider, Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek
Summary: In fit patients with CLL, venetoclax-obinutuzumab, with or without ibrutinib, showed superior results compared to chemoimmunotherapy as a first-line treatment, with higher rates of undetectable minimal residual disease and progression-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Xiaorong Yang, Hui Chen, Jinyu Man, Tongchao Zhang, Xiaolin Yin, Qiufeng He, Ming Lu
Summary: Leukemia incidence in the United States gradually increased over the past decades, but has started to decline in recent years. The 5-year relative survival rate of leukemia patients has improved incrementally over time, especially among young patients. There are significant disparities among different sexes, races, histological subtypes, and age groups, highlighting the need for precise causes control and innovative treatments.
Article
Cell Biology
Chi-Ling Chiang, Eileen Y. Hu, Lingqian Chang, Jadwiga Labanowska, Kevan Zapolnik, Xiaokui Mo, Junfeng Shi, Tzyy-Jye Doong, Arletta Lozanski, Pearlly S. Yan, Ralf Bundschuh, Logan A. Walker, Daniel Gallego-Perez, Wu Lu, Meixiao Long, Sanggu Kim, Nyla A. Heerema, Gerard Lozanski, Jennifer A. Woyach, John C. Byrd, Ly James Lee, Natarajan Muthusamy
Summary: This study used a microchannel electroporation technique to investigate the hematopoietic stem cells in chronic lymphocytic leukemia, confirming the existence of clonal hematopoietic stem cells and their differential drug sensitivity. Furthermore, the existence of CLL LICs was validated in both patient and mouse models. Additionally, differential protein ubiquitination and unfolding response were found in GATA2(high) CLL-HSCs, which significantly affected drug sensitivity.
Article
Oncology
Koji Sasaki, Fadi G. Haddad, Nicholas J. Short, Nitin Jain, Ghayas Issa, Elias Jabbour, Hagop Kantarjian
Summary: Since 2000, the treatment outcomes of Ph-positive CML have significantly improved. However, there are still differences in outcomes among patient subsets, including age and income factors.
Article
Oncology
Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M. Fernandes, Alberto J. Arribas, Abdul K. Hilli, Kjetil Tasken, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjonnfjord, Tero Aittokallio, Sigrid S. Skanland
Summary: This study analyzes the activity and cellular effects of PI3K inhibitors in CLL, finds novel treatment vulnerabilities, and suggests that ex vivo functional profiling can stratify PI3Ki responders.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Maddalena Marconato, Yacine Maringer, Juliane S. Walz, Annika Nelde, Jonas S. Heitmann
Summary: Immunosurveillance of cancer is crucial for identifying therapeutic targets. In this study, the immunopeptidome of chronic lymphocytic leukemia (CLL) cells was analyzed to investigate its association with clinical characteristics and disease outcome. The findings suggest that the presentation of a diverse range of peptides was linked to reduced relapses, and patients with a high number of presented peptides showed a more favorable disease course. These results support the development of T cell-based immunotherapeutic strategies for CLL.
Review
Hematology
Muhammad Hossein Ashoub, Amirreza Naseri, Parisa Mohammadi, Masoud Mohammadi
Summary: The therapeutic impact of ofatumumab on patients with chronic lymphocytic leukemia (CLL) has been widely studied. However, there is a lack of pooled assessment on the treatment effect of ofatumumab compared to non-ofatumumab regimens. This meta-analysis evaluated the efficacy of ofatumumab-based treatment using data from clinical studies and found that there was a significant improvement in progression-free survival (PFS) but no significant difference in overall survival (OS) between ofatumumab-based therapy and non-ofatumumab therapy.
ANNALS OF HEMATOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kristan V. Piroeva, Charlotte Mcdonald, Charalampos Xanthopoulos, Chelsea Fox, Christopher T. Clarkson, Jan-Philipp Mallm, Yevhen Vainshtein, Luminita Ruje, Lara C. Klett, Stephan Stilgenbauer, Daniel Mertens, Efterpi Kostareli, Karsten Rippe, Vladimir B. Teif
Summary: This study compared the nucleosome positions in chronic lymphocytic leukemia (CLL) patients and healthy individuals, and found significant changes in nucleosome positioning in CLL. The spacing between nucleosomes was shortened, and changes in nucleosome occupancy were linked to chromatin remodeling and reduced DNA methylation. Nucleosome positioning can be used to classify CLL subtypes and monitor disease progression.
Article
Dermatology
Yingzhi Qian, Paul Johannet, Amelia Sawyers, Jaehong Yu, Iman Osman, Judy Zhong
Summary: The study found that racial disparities among cutaneous melanoma patients have worsened from before the year 2000 to 2010 or later. Patients with localized disease across all minority groups suffered increasing disparity, highlighting the need for improved postdiagnosis management for minorities to mitigate disparity and improve survival.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2021)
Article
Hematology
Delphine Tardivon, Mateusz Antoszewski, Nadine Zangger, Marianne Nkosi, Jessica Sordet-Dessimoz, Rudi Hendriks, Ute Koch, Freddy Radtke
Summary: NOTCH1 gain-of-function mutations are common in B-cell chronic lymphocytic leukemia, and play a role in disease progression and chemotherapy resistance. In an in vivo mouse model of CLL, activation of Notch signaling facilitated disease initiation and promoted CLL cell proliferation and disease progression, while inhibition of Notch signaling delayed disease induction.
Review
Pathology
Magdalena Czader, Catalina Amador, James R. Cook, Devang Thakkar, Clay Parker, Sandeep S. Dave, Ahmet Dogan, Amy S. Duffield, Reza Nejati, German Ott, Wenbin Xiao, Mariusz Wasik, John R. Goodlad
Summary: This article discusses the progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and B-cell prolymphocytic leukemia (B-PLL). The study highlights the complexity and diagnostic challenges of these diseases, as well as the importance of molecular genetic studies in diagnosis and treatment.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
(2023)
Article
Oncology
Junguo Cao, Weijia Yan, Guihong Li, Zhixin Zhan, Xinyu Hong, Hong Yan
Summary: This study conducted a systematic epidemiological and clinical analysis of meningiomas. The study found that most meningioma patients were over the age of 60, and the incidence rates were higher in females, black individuals, and non-Hispanic individuals, and increased with age. Older age, male sex, black race, and tumor size may be important prognostic factors for meningioma cases, and tumor resection can substantially improve survival among meningioma patients.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Livius Penter, Satyen H. Gohil, Caleb Lareau, Leif S. Ludwig, Erin M. Parry, Teddy Huang, Shuqiang Li, Wandi Zhang, Dimitri Livitz, Ignaty Leshchiner, Laxmi Parida, Gad Getz, Laura Z. Rassenti, Thomas J. Kipps, Jennifer R. Brown, Matthew S. Davids, Donna S. Neuberg, Kenneth J. Livak, Vijay G. Sankaran, Catherine J. Wu
Summary: The study demonstrates the utility of somatic mtDNA mutations as in vivo barcodes for chronic lymphocytic leukemia, showing that these mutations can mark cancer subclones that evolve over time. The mtDNA mutations reflect disease history and provide natural genetic barcodes to study cancer subclonal dynamics in individual patients.
Review
Oncology
Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer
Summary: Telomeres play a crucial role in chronic lymphocytic leukemia (CLL), with their dysfunction shaping the disease progression. Members of the shelterin complex and TERT activation are closely associated with CLL cell survival and proliferation.
FRONTIERS IN ONCOLOGY
(2021)
Letter
Hematology
Preetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, Chi Young OK, Lucy Navsaria, Loretta Nastoupil, Hun Ju Lee, Guilin Tang, C. Cameron Yin, Maria Badillo, Ranjit Nair, Shaoying Li, Keyur M. Patel, Christopher Flowers, Francisco Vega, Linghua Wang, Michael L. Wang
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Oncology
Bradford S. Hoppe, Ranjana Advani, Sarah A. Milgrom, Richard L. Bakst, Leslie K. Ballas, Bouthaina S. Dabaja, Christopher R. Flowers, Chul S. Ha, David B. Mansur, Monika L. Metzger, Chelsea C. Pinnix, John P. Plastaras, Kenneth B. Roberts, Sonali M. Smith, Stephanie A. Terezakis, Jessica M. Kirwan, Louis S. Constine
Summary: The purpose of the study was to develop evidence-based guidelines for treating primary mediastinal B cell lymphoma (PMBCL) in adolescents and young adults. Through a systematic review and Delphi framework, consensus guidelines were developed based on the 5-point Deauville scale for EOC PET response. The guidelines cover various treatment approaches, including chemoimmunotherapy regimens, consolidative radiation therapy, and adaptive approaches based on EOC PET/CT response.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Oncology
Karine A. Al Feghali, Penny Fang, Maria Gule-Monroe, Sarah Milgrom, Joseph D. Khoury, Jillian R. Gunther, Tommy Sheu, Ranjit Nair, Sairah Ahmed, Raphael Steiner, Paolo Strati, Elizabeth J. Shpall, Yago L. Nieto, Chitra Hosing, Loretta J. Nastoupil, Jason R. Westin, Sattva S. Neelapu, Nathan Fowler, Christopher Flowers, Chelsea C. Pinnix, Bouthaina S. Dabaja
Summary: The distribution of baseline disease can impact the prognosis of patients with secondary CNS DLBCL, with those having localized disease potentially benefiting from stem cell transplantation post-Radiation Therapy. Receipt of SCT, response after RT, and presence of localized disease were associated with improved overall survival and CNS-disease-free survival.
LEUKEMIA & LYMPHOMA
(2021)
Article
Multidisciplinary Sciences
Shaojun Zhang, Vivian Changying Jiang, Guangchun Han, Dapeng Hao, Junwei Lian, Yang Liu, Rongjia Zhang, Joseph McIntosh, Ruiping Wang, Minghao Dang, Enyu Dai, Yuanxin Wang, David Santos, Maria Badillo, Angela Leeming, Zhihong Chen, Kimberly Hartig, John Bigcal, Jia Zhou, Rashmi Kanagal-Shamanna, Chi Young Ok, Hun Lee, Raphael E. Steiner, Jianhua Zhang, Xingzhi Song, Ranjit Nair, Sairah Ahmed, Alma Rodriquez, Selvi Thirumurthi, Preetesh Jain, Nicolaus Wagner-Bartak, Holly Hill, Krystle Nomie, Christopher Flowers, Andrew Futreal, Linghua Wang, Michael Wang
Summary: This study investigates the mechanisms driving resistance to treatment in mantle cell lymphoma (MCL) by analyzing the cellular and molecular heterogeneity within patients using single-cell sequencing. The researchers found temporal activation of cancer hallmark pathways and acquisition of 17q in refractory MCL, leading to upregulation of BIRC5/survivin expression. They demonstrate that targeting BIRC5 results in effective tumor inhibition in preclinical models and also identify changes in the tumor microenvironment in refractory MCL, including decreased CD8+ T cells and aberrant cell-to-cell communication networks.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
Andres Chang, Mallory K. Ellingson, Christopher R. Flowers, Robert A. Bednarczyk
Summary: The study found that vaccination rates for influenza are higher in cancer patients, but there is still room for improvement. Men and women with solid tumors and hematological malignancies have significantly higher vaccination rates compared to those without cancer, emphasizing the need for enhancing vaccine compliance to prevent complications.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Hematology
Carla Casulo, Jesse G. Dixon, Fang-Shu Ou, Eva Hoster, Bruce A. Peterson, Howard S. Hochster, Pauline Brice, Marco Ladetto, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Tina Nielsen, Franck Morschhauser, Mathias Rummel, Anton Hagenbeek, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers
Summary: Limited data exists on the clinical features and outcomes of elderly patients with follicular lymphoma (FL). In a pooled analysis of individual patient data from first-line randomized controlled trials, age over 70 was a significant predictor of overall survival and progression-free survival in FL patients. However, age alone should not exclude elderly patients from standard treatments or clinical trials.
Article
Hematology
Reem Karmali, Jeffrey M. Switchenko, Subir Goyal, Krithika Shanmugasundaram, Michael C. Churnetski, Bhaskar Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Max J. Gordon, Alexey Danilov, Natalie S. Grover, Narendranath Epperla, Stephanie Mathews, Madelyn Burkart, Yazeed Sawalha, Brian T. Hill, Nilanjan Ghosh, Steven Park, David A. Bond, Kami J. Maddocks, Talha Badar, Timothy S. Fenske, Mehdi Hamadani, Jin Guo, Mary Malecek, Brad S. Kahl, Peter Martin, Kristie A. Blum, Christopher R. Flowers, Jonathon B. Cohen
Summary: The study analyzed clinical outcomes and survival predictors of patients with newly diagnosed mantle cell lymphoma treated with rituximab, finding that younger patients had significantly higher survival rates compared to older patients, and maintenance rituximab may mitigate the negative impact of age on survival.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Max L. Goldman, Jimmy J. Mao, Christopher S. Strouse, Wanqi Chen, Manali Rupji, Zhengjia Chen, Matthew J. Maurer, Oscar Calzada, Michael Churnetski, Christopher R. Flowers, James R. Cerhan, Brian K. Link, Carrie A. Thompson, Jonathon B. Cohen
Summary: The study found limited role for routine surveillance imaging in FL patients who complete front-line therapy. Future studies should evaluate which patients may benefit from a more aggressive surveillance approach and explore novel methods of relapse detection.
Article
Oncology
Hua-Jay J. Cherng, Hubert H. Chuang, Raphael Steiner, Luis Fayad, Paolo Strati, Ranjit Nair, Fredrick Hagemeister, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Christopher R. Flowers, Felipe Samaniego, Maria Rodriguez, Homer A. Macapinlac, Lei Feng, Jason Westin
Summary: This study suggests that early PET/CT may predict treatment failure in patients with relapsed or refractory DLBCL, highlighting the potential benefits of early therapy changes for those who do not respond well to salvage chemotherapy. Further investigation into non-chemotherapy treatments based on early PET/CT findings could be valuable for future clinical trials.
LEUKEMIA & LYMPHOMA
(2022)
Article
Biochemistry & Molecular Biology
Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly Amelsberg, Sean M. Devlin, Raymone Pajarillo, John B. Slingerland, Silvia Beghi, Pamela S. Herrera, Paul Giardina, Annelie Clurman, Emmanuel Dwomoh, Gabriel Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schluter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel-Angel Perales, Craig W. Freyer, Alfred Garfall, Shannon Gier, Sunita Nasta, Daniel Landsburg, James Gerson, Jakub Svoboda, Justin Cross, Elise A. Chong, Sergio Giralt, Saar Gill, Isabelle Riviere, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R. M. van den Brink, Marco Ruella
Summary: This study investigated the changes in the intestinal microbiome of patients with B cell lymphoma and leukemia after receiving anti-CD19 CAR T cell therapy, and found that these changes are associated with clinical outcomes.
Review
Immunology
Nikeshan Jeyakumar, Melody Smith
Summary: Cellular therapies have revolutionized the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Autologous CAR T cells have shown promising results in achieving complete remission, but a significant portion of patients still relapse or progress. Allogeneic CAR T cells may offer a solution by addressing the limitations of autologous therapy and providing a more sustainable platform for cell therapies.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Alfred Ian Lee, Leah E. Masselink, Laura M. De Castro, Ariela L. Marshall, Nathan T. Connell, Georgette A. Dent, Josel Fritz, Morgan Homer, Tiffany L. Lucas, Rakhi P. Naik, Marquita Nelson, Casey L. O'Connell, Anita Rajasekhar, Robby J. Reynolds, Deva Sharma, Melody Smith, Lachelle D. Weeks, Clese E. Erikson
Summary: Burnout is common among hematologists and oncologists, but little is known about the impact of compensation and clinical support staff on burnout. A survey conducted by the American Society of Hematology in 2019 revealed that compensation plans solely based on clinical productivity were significantly associated with high burnout, while plans that included both productivity and salary showed no significant association. Female gender was associated with high burnout among academic physicians, and higher utilization of advanced practice providers was associated with lower burnout among community physicians.
Correction
Biochemistry & Molecular Biology
Melody Smith, Anqi Dai, Guido Ghilardi, Kimberly V. Amelsberg, Sean M. Devlin, Raymone Pajarillo, John B. Slingerland, Silvia Beghi, Pamela S. Herrera, Paul Giardina, Annelie Clurman, Emmanuel Dwomoh, Gabriel Armijo, Antonio L. C. Gomes, Eric R. Littmann, Jonas Schluter, Emily Fontana, Ying Taur, Jae H. Park, Maria Lia Palomba, Elizabeth Halton, Josel Ruiz, Tania Jain, Martina Pennisi, Aishat Olaide Afuye, Miguel-Angel Perales, Craig W. Freyer, Alfred Garfall, Shannon Gier, Sunita Nasta, Daniel Landsburg, James Gerson, Jakub Svoboda, Justin Cross, Elise A. Chong, Sergio Giralt, Saar I. Gill, Isabelle Riviere, David L. Porter, Stephen J. Schuster, Michel Sadelain, Noelle Frey, Renier J. Brentjens, Carl H. June, Eric G. Pamer, Jonathan U. Peled, Andrea Facciabene, Marcel R. M. van den Brink, Marco Ruella
Article
Hematology
Michael D. Jain, Melody Smith, Nirali N. Shah
Summary: The clinical use of CAR T-cell therapy is expanding due to increasing indications for treatment and new investigational products. Standard diagnostic criteria for CRS and ICANS, along with the use of tocilizumab and corticosteroids, have facilitated its widespread use. Preemptive interventions have improved safety, but persistent or progressive toxicities still pose challenges.
Editorial Material
Hematology
Melody Smith, Kate A. Markey
Summary: This study found that pediatric allo-HSCT patients with high microbial diversity prior to transplantation had longer overall survival and a lower incidence of acute GVHD. This is consistent with previous findings in adult allo-HSCT recipients. However, a key difference in this study is that the post-neutrophil engraftment microbiome was not associated with outcome, unlike in adults.